Current Opinion in Allergy and Clinical Immunology, published by Lippincott Williams & Wilkins, is a pivotal journal that serves as a key resource for professionals in the fields of immunology and allergy. With an ISSN of 1528-4050 and an E-ISSN of 1473-6322, this journal presents cutting-edge reviews of the latest research findings, methodologies, and therapeutic approaches in the management of allergic and immunological disorders. With a Q3 category ranking in both Immunology and Allergy for 2023, and a Scopus rank of #103 in Immunology and Allergy, it reflects a solid position within the scientific community. Operating in the highly dynamic fields of immunology and clinical practice since its inception in 2001, the journal aims to harmonize emerging research trends with clinical applications to enhance patient outcomes. Although it does not currently offer Open Access options, the journal's substantial impact factor attests to its significance as a scholarly resource. By disseminating high-quality reviews and expert opinions, Current Opinion in Allergy and Clinical Immunology continues to foster knowledge advancement and professional development among researchers, practitioners, and students alike.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

ALLERGOLOGY INTERNATIONAL is a prestigious, peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Published by the Japanese Society of Allergology, this Open Access journal has been democratizing knowledge since 1996, providing a platform for the latest findings and clinical practices in the management of allergic diseases. Its impressive Q1 ranking in both Immunology and Allergy** and **Medicine (miscellaneous)** categories in 2023 highlights its significance in the global scientific community, with a commendable Scopus ranking of #31 out of 233 in the field of immunology. The journal's focus on innovative research, comprehensive reviews, and case studies ensures that it remains a vital resource for researchers, healthcare professionals, and students alike. Situated in Tokyo, Japan, it continues to bridge gaps in allergy-related health information and foster international collaboration among scholars.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

Postepy Dermatologii i Alergologii is a distinguished Open Access journal published by TERMEDIA PUBLISHING HOUSE LTD, dedicated to advancing the fields of Dermatology and Immunology and Allergy. Since its inception in 2003, this journal has served as a vital platform for researchers and practitioners alike, promoting knowledge sharing and collaboration in Poland and beyond. With a current impact ranking placing it in the Q3 quartile for both Dermatology and Immunology and Allergy categories, it plays a significant role in contributing to academic discourse within these fields. The journal is indexed in Scopus, with respectable rankings reflecting its relevance and quality—#65/142 in Dermatology and #163/233 in Immunology and Allergy. Researchers are encouraged to explore a vast array of innovative studies and reviews, making it an essential resource for anyone seeking to stay at the forefront of dermatological and allergic research. For those interested in discovering groundbreaking findings and contributing to the ongoing dialogue in these disciplines, Postepy Dermatologii i Alergologii offers not only free accessibility but also a commitment to scholarly excellence.

Therapeutic Advances in Allergy and Rhinology, published by SAGE Publications Inc, is an esteemed journal that focuses on advancing the fields of allergy and rhinology through innovative and impactful research. As an Open Access journal, it provides a platform for researchers, clinicians, and students to share significant findings and therapeutic developments aimed at improving patient outcomes related to allergic conditions and nasal disorders. The journal aims to publish high-quality peer-reviewed articles, reviews, and case studies that contribute to a deeper understanding of the pathophysiology and management of allergies and rhinological conditions. By fostering collaborative dialogue across various disciplines, Therapeutic Advances in Allergy and Rhinology plays a crucial role in enhancing clinical practice and guiding future research in this vital area of health. With an ISSN of 2753-4030, the journal continues to establish itself as a key resource for anyone involved in allergy and rhinology research and practice.

Welcome to the American Journal of Rhinology & Allergy, a leading publication in the fields of otolaryngology and immunology, published by SAGE Publications Inc. Since its inception in 2009, this journal has played a pivotal role in disseminating cutting-edge research and reviews, addressing critical topics related to sinus disease, allergic disorders, and respiratory health. With an impressive Scopus ranking that places it in the top quartiles of both immunology and medicine, the journal garners about a 90th percentile ranking in otorhinolaryngology, reflecting its significance in advancing medical knowledge and clinical practice. The American Journal of Rhinology & Allergy aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers and professionals to explore innovative therapies and treatment protocols. Access options include traditional subscription models to ensure comprehensive support for the academic community. Join our efforts to enhance understanding and treatment in the critical area of rhinology and allergy.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.